Passage BIO, Inc. 8-K

What Happened
Passage Bio, Inc. (PASG) filed an 8-K on April 28, 2026 disclosing a Restructuring Plan as part of a review of strategic alternatives. The company announced it will reduce its workforce by approximately 75%, with implementation expected to be substantially complete in the second and third quarters of 2026. Impacted employees are eligible for severance benefits that are contingent on executing (and not revoking) a severance agreement that includes a general release of claims. Passage Bio expects to record aggregate severance and exit costs of about $3.3 million, primarily in Q2 2026, but noted actual costs may differ and additional costs could arise.

Key Details

• Filing date: April 28, 2026 (Form 8-K, Item 2.05).
• Workforce reduction: approximately 75% of employees.
• Expected costs: ~$3.3 million in aggregate severance and exit costs, to be recorded mainly in Q2 2026.
• Timing: implementation substantially complete in Q2 and Q3 2026; severance contingent on signed, non-revoked release agreements.

Why It Matters
This restructuring is a material operational change intended to reduce operating expenses and is tied to Passage Bio’s ongoing review of strategic alternatives. The $3.3M charge is the company’s current estimate for termination-related costs, but the filing warns actual expenses and future impacts could differ and additional costs may occur. Investors should watch for updates on the strategic review, any further disclosures of costs or timing, and how workforce reductions may affect the company’s programs and financial results.